Interní Med. 2008; 10(11): 494-497

Oral antidiabetic agents - treatment of type 2 diabetes

MUDr. Pavlína Pi»hová
Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze

Oral antidiabetic agents (OAD) are preparations used in Type 2 Diabetes mellitus treatment. There is important to manage both metabolic disorders in diabetic patients – impaired insulin sensitivity and dysfunction in insulin secretion as well. Basic tools in optimal metabolic control are preparations that influence mainly fasting glycemia (metformin, thiazolidindions) and mainly postprandial glycemia (acarbose, insulin secretagogues, incretin mimetics). Incretin mimetics work in more levels of glucose metabolism regulations and form a new quality in antidiabetic treatment. There is possible to combine various species of oral antidiabetic agents or combine OAD with insulin therapy.

Keywords: Key words: type 2 diabetes mellitus, oral antidiabetic agents, insulin secretagogs, biguanids, thiazolidindions, incretin mimetics.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»hová P. Oral antidiabetic agents - treatment of type 2 diabetes. Interní Med. 2008;10(11):494-497.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahmann AJ, Riedle MC. et al. Současná perorální antidiabetika určená k léčbě diabetu 2. typu. Medicína po promoci 2002; 3(5): 10-16.
    2. Bell, DSH. Current status of diabetes treatment. South Med J 2002, 95 (1): 24-29. Go to original source... Go to PubMed...
    3. Fonseca, V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes melitus. Curr Med Res Opin 2003, 19 (7): 635-641. Go to original source... Go to PubMed...
    4. Garber AJ. Metformin and other biguanides: Pharmacology and therapeutic usage. In Int Textbook of Diabetes Mellitus, Third Edition, edited by DeFronzo RA, Feranini E et al. John Wiley&Sons Ltd., 2004: 851-869. Go to original source...
    5. Harrity, T, Farrely, D. et al. Muraglitazar, a novel dual alfa/gamma peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes. 2006, 55 (1): 240 - 248. Go to original source... Go to PubMed...
    6. Kendall, DM. Postprandial Blood Glucose in the Management of Type 2 Diabetes: The Emerging Role of Incretin Mimetics. Medscape Diabetes and Endocrinology. 2005, 7(2) http://www.medscape.com/viewarticle/515693.
    7. Kvapil, M. Moľnosti ovlivnění funkce B-buněk glitazony. Farmakoterapie 2005; 1(1): 26-29.
    8. Oląovský, J. Jak pouľívat perorální antidiabetika - algoritmy výběru. Farmakoterapie 2005; 1(1): 81-85.
    9. Oląovský, J. Kombinace perorálních antidiabetik ve světle nových studií. Farmakoterapie 2005; 2(1): 86-89.
    10. Padwal, R, Majumdar, SR. et al. A systematic review of drug therapy to delay or present type 2 diabetes. Diabetes Care 2005, 28 (3): 736-744. Go to original source... Go to PubMed...
    11. Ratner, RE. Therapeutic Role of Incretin Mimetics. Medscape Diabetes and Endocrinology. 2005, 7(1) http://www.medscape.com/viewarticle/506476.
    12. Tibaldi J. Preserving insulin secretion in Type 2 diabetes mellitus. Expert Rev Endocrinol Metab. 2008; 3(2): 147-159. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.